(Q81307965)
Statements
Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer (English)
Robert Bleichrodt
Manuel Koppe
Frank van Schaijk
Jan Roos
Paul van Leeuwen
Karl-Heinz Heider